Showing 3861-3870 of 9152 results for "".
- Novan, Inc. Acquires EPI Healthhttps://practicaldermatology.com/news/novan-inc-acquires-epi-health/2461106/EPI Health is now a Novan Company. The EP Group today announced the acquisition of EPI Health, LLC by Novan, Inc. EPI Health is a leading company in the US dermatology sector with an established sales force and commercial team with existing, deep market relationships across the de
- PCA SKIN® Recognizes Third Annual National Peel Dayhttps://practicaldermatology.com/news/pca-skin-recognizes-third-annual-national-peel-day/2461104/PCA SKIN® wants to know #HowYouPeelin, as the company celebrates the third annual National Peel Day, Thursday, highlighting their latest peel innovation, new partnership, special promotion for accounts, and a host of social media activities.&
- Nancy Beesley Joins Dermavant Board of Directorshttps://practicaldermatology.com/news/nancy-beesley-joins-dermavant-board-of-directors/2461101/Nancy Beesley has been appointed to Dermavant Sciences’ Board of Directors. She joins Dermavant with more than 25 years of experience in commercializing and branding therapeutics for the treatment of various dermatological, ophthalmic, and neurologica
- Differin Doubles Down on Retinoid Education Week with New Campaign Launchhttps://practicaldermatology.com/news/differin-doubles-down-on-retinoid-education-week-with-new-campaign-launch/2461100/Differin Gel is launching a digital and audio marketing campaign that will culminate in a strategic partnership with Acast Creative and the
- Aquaphor Unveils New Purpose-Driven Brand Campaignhttps://practicaldermatology.com/news/aquaphor-unveils-new-purpose-driven-brand-campaign/2461099/Aquaphor is launching its first-ever brand purpose campaign, "Before & Aquaphor." Inspired by the growing field of psychodermatology, this new integrated campaign highlights the connection between our skin health and our emotional well-being.
- Study: Melanoma Referral Centers Worldwide Adopt Systemic Therapies, Reduce Lymph Node Removal Surgerieshttps://practicaldermatology.com/news/study-melanoma-referral-centers-worldwide-adopt-systemic-therapies-reduce-lymph-node-removal-surgeries/2461097/Lymph node removal surgery for patients with high-risk melanoma has become less common over the past few years while the use of targeted and immune therapies has risen rapidly at melanoma referral centers worldwide, an international group of researchers found. However, a large degree of
- Successful Topline Results Seen for Hallura's New BiOLinkMatrix HA Aesthetic Fillershttps://practicaldermatology.com/news/successful-topline-results-seen-for-halluras-new-biolinkmatrix-ha-aesthetic-fillers/2461096/Hallura Ltd’s hyaluronic acid (HA) dermal fillers with its proprietary BiOLinkMatrix platform performed well for lip enhancement, nasolabial folds correction. and cheek enhancement, according to topline results. The proprietary Bi
- Butt First, Endo Launches New Qwo Consumer Campaignhttps://practicaldermatology.com/news/butt-first-endo-launches-new-qwo-consumer-campaign/2461095/Endo International plc is kicking off more than 200 patient events across the United States as part of Butt First, a new direct-to-consumer awareness campaign about Qwo (collagenase clostridium histolyticum-aaes). Qwo received FDA approval in Jul
- Business News: Taro to Acquire Alchemee From Galdermahttps://practicaldermatology.com/news/business-news-taro-to-acquire-alchemee-from-galderma/2461087/Taro Pharmaceutical Industries Ltd. Is buying Alchemee, formerly The Proactiv Company, from Galderma. The acquisition is subject to customary closing conditions and any necessary regulatory approvals. Financial terms of the transaction have not been disclosed. "We are exc
- Study Establishes Optimal Drug Delivery Settings for Needle-free Jet Injectorshttps://practicaldermatology.com/news/study-establishes-optimal-drug-delivery-settings-for-needle-free-jet-injectors/2461085/Needle-free jet injectors have been used in dermatological practice for many years for the nearly pain-free transdermal drug delivery for indications such as hypertrophic scars, keloids, and warts, but predefined clinical endpoints that guide physicians to choose optimal device settings have not